Welsh School of Pharmacy, Cardiff University, King Edward VII Avenue, Cardiff, CF10 3NB, UK.
Future Med Chem. 2012 Apr;4(5):625-50. doi: 10.4155/fmc.12.10.
The search for new anti-hepatitis C virus (HCV) therapeutics continues as the current treatment, consisting of PEGylated IFN-α and ribavirin, is of limited efficacy, nonspecific and can cause significant side effects. Modified nucleoside analogues with improved efficacy and selectivity, may become the backbone of the future standard of care for anti-HCV therapies. Several families of modified nucleoside are known to inhibit HCV RNA-dependent RNA polymerase, a vital enzyme for viral replication. Ongoing efforts are focused on improvement of potency, selectivity and delivery of antiviral nucleoside analogues, with several recent promising advances into clinical trials. This review summarizes the current progress in the development of new anti-HCV nucleoside and nucleotide prodrugs.
抗丙型肝炎病毒 (HCV) 治疗药物的研发仍在继续，因为目前的治疗方法（聚乙二醇干扰素-α和利巴韦林）疗效有限、非特异性且可能导致严重的副作用。具有更高疗效和选择性的修饰核苷类似物可能成为未来 HCV 治疗标准护理的基础。几种修饰核苷家族被认为可以抑制 HCV RNA 依赖性 RNA 聚合酶，这是病毒复制的关键酶。目前的研究重点是提高抗病毒核苷类似物的效力、选择性和递送效率，最近有几项很有前途的进展已经进入临床试验。本文综述了新型抗 HCV 核苷和核苷酸前药的研发进展。
